Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial — Barrons.com

By Mackenzie TatananniShares of Kodiak Sciences headed for their best session on record Monday after two experimental eye drugs succeeded in a late-stage trial, positioning the biopharmaceutical company to get its first product to market.Kodiak Sciences nannounced that Zenkuda and KSI-501, two expe…